Drugs / LY3325656
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03115099 | May 2017 → Apr 2018 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY3325656 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03115099 ↗ |
| Route | Oral | “Administered orally” NCT03115099 ↗ |